Specialty CRO QCTR Selects Medidata CTMS to Streamline Clinical Trials
Medidata Solutions
announced that specialty contract research organization (CRO) QCTR Ltd. has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.
Scotland-based QCTR was founded in 2006 to fill an ndustry need for CRO expertise in central nervous system (CNS) clinical research. As their study pipeline grew, QCTR realized that a commercial trial management solution was necessary to efficiently do more with existing resource.
“Compared to other available systems, Medidata’s SaaS-based CTMS solution offered much greater value in terms of richness of features, speed of set-up, flexibility, ease-of-use and global accessibility—without requiring extensive up-front investment,” said Susan McGoldrick, Managing Director, QCTR. “It’s evident that Medidata CTMS was developed with CRO-specific needs in mind. We’re especially excited about the opportunities to more proactively manage the performance of investigator sites and streamline how we pay them—key aspects in our strategy to maintain our sites’ high satisfaction and patient recruitment excellence as we scale our business.”
QCTR anticipates that Medidata CTMS will greatly reduce the time and effort needed to track key milestones and operational metrics across their clinical studies and sites—both from the perspective of data entry as well as timely access to information and reports. As a result, study managers and monitors should be able to maintain a tight handle on issues despite increased study volumes and quickly follow up with sites.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025